IL13 and allergic asthma: Importantly, despite the lack of GRE-mediated transcriptional properties, systemic VBP15 treatment is at least as effective as prednisolone, a traditional glucocorticoid treatment, at reducing pulmonary NFκB activity, leukocyte degranulation, and the release of Th2 pro-inflammatory cytokines (i.e. IL-13) in the lungs of a murine model of ovalbumin-induced allergic asthma [3].